Skip to Content

Notice

Advisory Committee; Renewals

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing the renewals of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the charters of the committees listed below for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed below. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pubic Law 92-463 (5 U.S.C. app. 2)).

DATES:

Authority for these committees will expire on the dates indicated below unless the Commissioner formally determines that renewal is in the public interest.

Name of committeeDate of expiration
Gastrointestinal Drugs Advisory CommitteeMarch 3, 2002
Advisory Committee for Reproductive Health DrugsMarch 23, 2002
Arthritis Advisory CommitteeApril 5, 2002
Veterinary Medicine Advisory CommitteeApril 24, 2002
Anesthetic and Life Support Drugs Advisory CommitteeMay 1, 2002
Blood Products Advisory CommitteeMay 13, 2002
Pulmonary-Allergy Drugs Advisory CommitteeMay 30, 2002
Drug Abuse Advisory CommitteeMay 31, 2002
Science Advisory Board to the National Center for Toxicological ResearchJune 2, 2002
Peripheral and Central Nervous System Drugs Advisory CommitteeJune 4, 2002
Psychopharmacologic Drugs Advisory CommitteeJune 4, 2002
Transmissible Spongiform Encephalopathies Advisory CommitteeJune 9, 2002
Science Board to the Food and Drug AdministrationJune 26, 2002
Allergenic Products Advisory CommitteeJuly 9, 2002
Cardiovascular and Renal Drugs Advisory CommitteeAugust 27, 2002
Endocrinologic and Metabolic Drugs Advisory CommitteeAugust 27, 2002
Oncologic Drugs Advisory CommitteeSeptember 1, 2002
Start Further Info Start Printed Page 64966

FOR FURTHER INFORMATION CONTACT:

Donna M. Combs, Committee Management Office (HFA-306), Food and Drug Administration, 5600 Fishers Lane, Rockville MD 20857, 301-827-5496.

Start Signature

Dated: October 23, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

End Signature End Further Info End Preamble

[FR Doc. 00-27835 Filed 10-30-00; 8:45 am]

BILLING CODE 4160-01-F